Effect of Herbal Supplement on Improving Sperm Virility

NCT ID: NCT07109622

Last Updated: 2025-08-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-08
• Study Completion Date: 2026-02-10

Brief Summary

The purpose of this study is to evaluate the efficacy of LN18178 on improving sperm virility.

Detailed Description

A total of 40 Males aged between 25-45 years will be included in the study. Assessment of inclusion and exclusion criteria will be done based on clinical and laboratory investigations. The eligible subjects will be randomized as per the computer-generated randomization list. The subjects will be assigned to either LN18178 - 400 mg or placebo arms at 1:1 ratio. The subjects will be instructed to take one capsule daily in the morning after breakfast for 12 weeks. A part from primary and secondary outcomes, the study will also record the vital signs and adverse events to evaluate the herbal composition safety and tolerability. The safety assessment of the LN18178 will also include routine laboratory investigations on blood, urine and clinical chemistry at screening and the final visit of the intervention.

Conditions

Healthy Human Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: HEALTH_SERVICES_RESEARCH
• Blinding Strategy: DOUBLE

Study Groups

LN18178

400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.

Group Type: EXPERIMENTAL

LN18178

Intervention Type: DIETARY_SUPPLEMENT

400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.

Placebo

One capsule to be consumed in the morning after breakfast for 12 Weeks

Group Type: OTHER

Placebo

Intervention Type: DIETARY_SUPPLEMENT

One capsule to be consumed in the morning after breakfast for 12 Weeks

Interventions

LN18178

400 mg, One capsule to be consumed in the morning after breakfast for 12 weeks.

Intervention Type: DIETARY_SUPPLEMENT

Placebo

One capsule to be consumed in the morning after breakfast for 12 Weeks

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Males aged between 25-45 years with a Body Mass Index (BMI) of 20-29 kg/m2.

2. Subjects with a history of infertility of at least 12 months despite regular unprotected intercourse.

3. Subjects with semen analysis showing abnormal sperm concentration (< 16 million/ml), progressive motility (< 30%), and total motility (< 42%), normal morphology (< 4%). (WHO guidelines- 6th edition, 2021)

4. Subjects with total testosterone ≥300 ng/dL.

5. Subjects who are willing to abstain from sexual activity that results in ejaculation for 3 to 5 days before semen analysis.

6. Subjects who are in a stable sexual relationship and sexually active during the study.

7. Subjects willing to use contraceptives during study period.

8. Subjects agree to maintain current diet and activity level.

9. No urogenital infection or anatomical abnormality of this system, including varicocele; no prior history of surgery in the pelvic area; no uncontrolled systemic illness, such as liver and gallbladder cancers, renal failure, thyroid disorders, and cerebral haemorrhage; no prior history of trauma to the testes; no unilateral testicular atrophy; no previous history of chemotherapy or treatment with anticoagulants, corticosteroids, testosterone and anti-androgen medications during the 8 weeks before the study.

10. Subject considered generally healthy as per health history and routine clinical investigations during screening.

11. Ability to understand the risks/benefits of the protocol and willing to sign the written informed consent.

Exclusion Criteria

1. Employees working on night shifts.

2. Subjects with identifiable cause for Oligoasthenoteratozoospermia (OAT) (includes Cryptorchidism, Orchitis and Radiation or chemotherapy etc.).

3. Subjects with Systolic >140 and Diastolic >90 mmHg blood pressure and Fasting blood glucose (FBG) >125 mg/dl.

4. Smokers and alcoholics.

5. Subjects underwent treatment for COVID 19 within the last 3 months or tested positive during the study will be excluded.

6. Subject with any physical disability that may limit sexual function.

7. Subjects with history of taking medications for oligospermia or any other sexual problems, including PDE-5 inhibitors, and dysfunctions related to genito-urinary system, muscular dystrophy and coagulation.

8. Subjects with clinical history of genital surgery, endocrine disorders e.g. hypopituitarism, pituitary tumors, hypo- and hyperthyroidism, hypogonadism, inherited (genetic and chromosomal) disorders, etc.

9. Subjects diagnosed with sleep apnea or related disorders.

10. Subjects consuming medications that can interfere with muscle mass such as corticosteroids, testosterone replacement or anabolic drugs.

11. Subjects who consume recreational drugs (such as cocaine, methamphetamine, marijuana, etc.) or chewable tobacco products.

12. Subjects having history of Benign Prostate Hyperplasia (BPH), stroke, myocardial infarction, coronary artery disease, cardiac failure, angina, life-threatening arrhythmia within the past 6 months.

13. Subjects under medications including vitamins, antidepressants, anticholinergics, inhaled beta agonists, anti- hyperlipidemic, psychotropics etc.

14. Subjects using any centrally acting anorectic agents, drugs that inhibit the absorption of nutrients and endocannabinoid neuromodulators during the two weeks prior to enrolment into the study.

15. Subjects who underwent major surgical procedures in last 6 months, which may affect their quality of life.

16. Subject with HIV positive or any other STDs.

17. History of psychiatric disorder that may impair the ability of subjects to provide written informed consent.

18. Subject has participated in a clinical study within the last 90 days prior to recruitment or concurrently participating in another study.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

GENCOR Lifestage Solutions

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Mr Machiraju Garga

Role: CONTACT

machiraju.gls@gmail.com

+91 8331015019

References

Abbasi B, Molavi N, Tavalaee M, Abbasi H, Nasr-Esfahani MH. Alpha-lipoic acid improves sperm motility in infertile men after varicocelectomy: a triple-blind randomized controlled trial. Reprod Biomed Online. 2020 Dec;41(6):1084-1091. doi: 10.1016/j.rbmo.2020.08.013. Epub 2020 Aug 20.

Reference Type: BACKGROUND

PMID: 33032908 (View on PubMed)

Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004 Aug;172(2):658-63. doi: 10.1097/01.ju.0000132389.97804.d7.

Reference Type: BACKGROUND

PMID: 15247755 (View on PubMed)

Pandit S, Biswas S, Jana U, De RK, Mukhopadhyay SC, Biswas TK. Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers. Andrologia. 2016 Jun;48(5):570-5. doi: 10.1111/and.12482. Epub 2015 Sep 22.

Reference Type: BACKGROUND

PMID: 26395129 (View on PubMed)

Yoon HS, Kim JR, Park GY, Kim JE, Lee DH, Lee KW, Chung JH. Cocoa Flavanol Supplementation Influences Skin Conditions of Photo-Aged Women: A 24-Week Double-Blind, Randomized, Controlled Trial. J Nutr. 2016 Jan;146(1):46-50. doi: 10.3945/jn.115.217711. Epub 2015 Nov 18.

Reference Type: BACKGROUND

PMID: 26581682 (View on PubMed)

Wang-Polagruto JF, Villablanca AC, Polagruto JA, Lee L, Holt RR, Schrader HR, Ensunsa JL, Steinberg FM, Schmitz HH, Keen CL. Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hypercholesterolemic postmenopausal women. J Cardiovasc Pharmacol. 2006;47 Suppl 2:S177-86; discussion S206-9. doi: 10.1097/00005344-200606001-00013.

Reference Type: BACKGROUND

PMID: 16794456 (View on PubMed)

Forest CP, Padma-Nathan H, Liker HR. Efficacy and safety of pomegranate juice on improvement of erectile dysfunction in male patients with mild to moderate erectile dysfunction: a randomized, placebo-controlled, double-blind, crossover study. Int J Impot Res. 2007 Nov-Dec;19(6):564-7. doi: 10.1038/sj.ijir.3901570. Epub 2007 Jun 14.

Reference Type: BACKGROUND

PMID: 17568759 (View on PubMed)

Srivastava MK, Singh G, Kodur RR, Yalamanchi A. A Combination of Punica granatum Fruit Rind and Theobroma cacao Seed Extracts Enhances Sexual Function in Aging Males in a Randomized, Double-blind, Placebo-controlled Study. Int J Med Sci. 2025 Jan 1;22(2):383-397. doi: 10.7150/ijms.99958. eCollection 2025.

Reference Type: BACKGROUND

PMID: 39781534 (View on PubMed)

Pandit SL, Yaligar D, Halemane M, Bhat A. A proprietary blend of standardized Punica granatum fruit rind and Theobroma cocoa seed extracts mitigates aging males' symptoms: A randomized, double-blind, placebo-controlled study. Int J Med Sci. 2022 Jul 11;19(8):1290-1299. doi: 10.7150/ijms.73645. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35928723 (View on PubMed)

Sreeramaneni PGA, Yalamanchi A, Konda MR, Cherukuri SHV, Maroon JC. A Proprietary Herbal Blend Containing Extracts of Punica granatum Fruit Rind and Theobroma cocoa Seeds Increases Serum Testosterone Level in Healthy Young Males: A Randomized, Double-Blind Placebo-Controlled Study. J Diet Suppl. 2023;20(3):411-427. doi: 10.1080/19390211.2022.2035037. Epub 2022 Feb 6.

Reference Type: BACKGROUND

PMID: 35129040 (View on PubMed)

Madireddy RK, Alluri KV, Somepalli V, Golakoti T, Sengupta K. Toxicological Assessments of a Proprietary Blend of Punica granatum Fruit Rind and Theobroma cacao Seed Extracts: Acute, Subchronic, and Genetic Toxicity Studies. J Toxicol. 2022 May 6;2022:3903943. doi: 10.1155/2022/3903943. eCollection 2022.

Reference Type: BACKGROUND

PMID: 35571381 (View on PubMed)

Asiedu-Gyekye IJ, Frimpong-Manso S, N'guessan BB, Abdulai Seidu M, Osei-Prempeh P, Kwaku Boamah D. Macro- and Microelemental Composition and Toxicity of Unsweetened Natural Cocoa Powder in Sprague-Dawley Rats. J Toxicol. 2016;2016:4783829. doi: 10.1155/2016/4783829. Epub 2016 Aug 17.

Reference Type: BACKGROUND

PMID: 27610134 (View on PubMed)

Boroujeni SN, Malamiri FA, Bossaghzadeh F, Esmaeili A, Moudi E. The most important medicinal plants affecting sperm and testosterone production: a systematic review. JBRA Assist Reprod. 2022 Aug 4;26(3):522-530. doi: 10.5935/1518-0557.20210108.

Reference Type: BACKGROUND

PMID: 35234023 (View on PubMed)

Krausz C. Male infertility: pathogenesis and clinical diagnosis. Best Pract Res Clin Endocrinol Metab. 2011 Apr;25(2):271-85. doi: 10.1016/j.beem.2010.08.006.

Reference Type: BACKGROUND

PMID: 21397198 (View on PubMed)

Al Wattar BH, Rimmer MP, Teh JJ, Mackenzie SC, Ammar OF, Croucher C, Anastasiadis E, Gordon P, Pacey A, McEleny K, Sangster P. Pharmacological non-hormonal treatment options for male infertility: a systematic review and network meta-analysis. BMC Urol. 2024 Jul 29;24(1):158. doi: 10.1186/s12894-024-01545-1.

Reference Type: BACKGROUND

PMID: 39075435 (View on PubMed)

Jo J, Lee SH, Lee JM, Jerng UM. Semen Quality Improvement in a Man with Idiopathic Infertility Treated with Traditional Korean Medicine: A Case Report. Explore (NY). 2015 Jul-Aug;11(4):320-3. doi: 10.1016/j.explore.2015.04.007. Epub 2015 Apr 28.

Reference Type: BACKGROUND

PMID: 26025007 (View on PubMed)

Terai K, Horie S, Fukuhara S, Miyagawa Y, Kobayashi K, Tsujimura A. Combination therapy with antioxidants improves total motile sperm counts: A Preliminary Study. Reprod Med Biol. 2019 Nov 28;19(1):89-94. doi: 10.1002/rmb2.12308. eCollection 2020 Jan.

Reference Type: BACKGROUND

PMID: 31956290 (View on PubMed)

Other Identifiers

GNC/SV/LN18178/25

Identifier Type: -

Identifier Source: org_study_id